We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biosimilars User Fee Language Mandates Study of Review Workload
Biosimilars User Fee Language Mandates Study of Review Workload
January 17, 2012
The FDA will contract with an independent firm to study workload volume and full costs associated with reviewing biosimilars applications under proposed statutory language for a user fee program.